Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

• Status: Completed
• Trial end date: 2016-02-16
• Target enrollment: 0
• Participant gender: All

Summary

This phase I trial studies the side effects and best dose of entinostat when given together with lapatinib ditosylate and trastuzumab in treating patients with breast cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes or has recurred (come back) at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected. Entinostat and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. Giving entinostat together with lapatinib ditosylate and trastuzumab may kill more tumor cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Entinostat; Histone Deacetylase Inhibitors; Immunoglobulins; Lapatinib; Trastuzumab; Trastuzumab biosimilar HLX02

Criteria

Inclusion Criteria:

• Patients have histological confirmation of invasive breast carcinoma

• Patients have locally recurrent or distant relapsed metastatic disease

• Patients have positive HER2 expression by immunohistochemistry (IHC) (3+) or fluorescence in situ hybridization (FISH) testing (> 2.0 ratio)

• Patients are able to swallow and retain oral medication (i.e., no uncontrolled vomiting, inability to swallow, or diagnosis of chronic malabsorption)

• Patients have Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Patients must have received prior trastuzumab for > 2 month period before disease recurrence or recurrence or progression while on trastuzumab-based therapy

• Patients have ability and willingness to sign written informed consent

• Female patients of childbearing potential (a female not free from menses > 2 years or not surgically sterilized) must be willing to use an adequate barrier method of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study; male patients who are able to father children must use an adequate barrier method of contraception

• Female patients of childbearing potential must have negative serum pregnancy test within 14 days of starting protocol therapy

• Patients with brain metastasis have no signs of progressive disease 4 months after the completion of brain metastasis treatment (radiation therapy, surgery, etc.) do not require anticonvulsants or corticosteroids, and have been off such drugs for at least 7 days

• Both men and women and members of all races and ethnic groups are eligible for this trial

Exclusion Criteria:

• Patients are receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, biological therapy and hormonal therapy) while taking study medication

• Serum bilirubin >= 1.5 x upper limit of normal (ULN)

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x ULN (with or without liver metastasis [mets])

• Absolute neutrophil count (ANC) < 1.5

• Hemoglobin =< 9

• Platelet =< 140,000

• Patients have an active infection and require intravenous (IV) or oral antibiotics

• Cardiac arrhythmia requiring maintenance medication

• History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

• Patients have a concurrent disease or condition that would make them inappropriate for study participation, or any serious medical disorder that would interfere with patients' safety

• Serum creatinine > 2.0 mg/dL